- « Previous
- Clinical Pharmacology
- Next »
Hytrin
CLINICAL PHARMACOLOGY
Hytrin
Pharmacodynamics
A. Benign Prostatic Hyperplasia (BPH)
The symptoms associated with BPH are related to bladder outlet obstruction, which is comprised of two underlying components: a static component and a dynamic component. The static component is a consequence of an increase in prostate size. Over time, the prostate will continue to enlarge. However, clinical studies have demonstrated that the size of the prostate does not correlate with the severity of BPH symptoms or the degree of urinary obstruction. The dynamic component is a function of an increase in smooth muscle tone in the prostate and bladder neck, leading to constriction of the bladder outlet. Smooth muscle tone is mediated by sympathetic nervous stimulation of alpha-l adrenoceptors, which are abundant in the prostate, prostatic capsule and bladder neck. The reduction in symptoms and improvement in urine flow rates following administration of terazosin is related to relaxation of smooth muscle produced by blockade of alpha-l adrenoceptors in the bladder neck and prostate. Because there are relatively few alpha-l adrenoceptors in the bladder body, terazosin is able to reduce the bladder outlet obstruction without affecting bladder contractility.
Terazosin has been studied in 1222 men with symptomatic BPH. In three placebo-controlled studies, symptom evaluation and uroflowmetric measurements were performed approximately 24 hours following dosing. Symptoms were quantified using the Boyarsky Index. The questionnaire evaluated both obstructive (hesitancy, intermittency, terminal dribbling, impairment of size and force of stream, sensation of incomplete bladder emptying) and irritative (nocturia, daytime frequency, urgency, dysuria) symptoms by rating each of the 9 symptoms from 0-3, for a total score of 27 points. Results from these studies indicated that terazosin statistically significantly improved symptoms and peak urine flow rates over placebo as follows:
| Symptom Score (Range 0-27) | Peak Flow Rate (mL/sec) | |||||||
| N | Mean Baseline | Mean Change (%) | N | Mean Baseline | Mean Change (%) | |||
Study 1 (10 mg)a | ||||||||
| Titration to fixed dose (12 wks) | ||||||||
| Placebo | 55 | 9.7 | -2.3 (24) | 54 | 10.1 | +1.0 (10) | ||
| Terazosin | 54 | 10.1 | -4.5 (45)* | 52 | 8.8 | +3.0 (34)* | ||
Study 2 (2, 5, 10, 20 mg)b | ||||||||
| Titration to response (24 wks) | ||||||||
| Placebo | 89 | 12.5 | -3.8 (30) | 88 | 8.8 | +1.4 (16) | ||
| Terazosin | 85 | 12.2 | -5.3 (43)* | 84 | 8.4 | +2.9 (35)* | ||
Study 3 (1, 2 , 5, 10 mg)c | ||||||||
| Titration to response (24 wks) | ||||||||
| Placebo | 74 | 10.4 | -1.1 (11) | 74 | 8.8 | +1.2 (14) | ||
| Terazosin | 73 | 10.9 | -4.6 (42)* | 73 | 8.6 | +2.6 (30)* | ||
|
Brand Name: Hytrin
Generic Name: Terazosin Hcl
Bookmark this page:
HypertensionGet tips on handling your hypertension. HytrinRelated DrugsHealth Resources
Drug NewsRxList HomeDrugs & Medications A-Z List Pill Identification Tool Drug Medical Dictionary Diseases & Conditions
About RxListContact RxListTerms & ConditionsPrivacy PolicySponsor PolicySite Map WebMD®MedScape®eMedicineHealth®MedicineNet® Copyright © 2008 by RxList Inc.
 RxList does not provide medical advice, diagnosis or treatment. See additional information. | ||||||||
2008 Election & Health Care on WebMD. Get Informed.
Updated & New